C-C motif chemokine ligand 2

Overview

C-C motif chemokine ligand 2 (CCL2), widely known as monocyte chemoattractant protein-1 (MCP-1), is a small secreted cytokine belonging to the CC chemokine family. It is encoded by the CCL2 gene and functions primarily as a potent chemoattractant that recruits monocytes, memory T cells, and dendritic cells to sites of tissue injury, infection, and inflammation. CCL2 exerts its effects predominantly through binding to its cognate receptor CCR2, triggering downstream signaling cascades that promote immune cell trafficking across vascular endothelium into inflamed tissues. As a central mediator of the innate and adaptive immune response, CCL2 is constitutively expressed at low levels in a wide range of cell types — including endothelial cells, smooth muscle cells, fibroblasts, astrocytes, and adipose-derived stem cells — and is rapidly upregulated in response to proinflammatory stimuli such as Tumour necrosis factor alpha (TNF-α), interleukin-1 beta, interleukin-6, and nuclear factor kappa B (NF-κB) activation.

Beyond its canonical role in monocyte recruitment, CCL2 has emerged as a pleiotropic signaling molecule with relevance across a broad spectrum of pathological conditions, including sepsis, chronic kidney disease, lupus nephritis, obesity-associated inflammation, periodontitis, spinal cord injury, diabetic wound healing, and cancer. Its intersection with oxidative stress pathways, matrix metalloproteinase activity (notably matrix metalloproteinase-9), and growth factors such as TGF-β1 positions it as a critical node in the inflammatory-fibrotic axis. Dysregulated CCL2 expression is increasingly recognized as both a biomarker of disease severity and a tractable therapeutic target, making it a subject of intense contemporary biomedical research.

Recent Publications Focus

Below is a summary of the newest research publications targeting C-C motif chemokine ligand 2 (sorted by publication date).

Recent studies have continued to position C-C motif chemokine ligand 2 (CCL2) as a key inflammatory and therapeutic target across infection, cancer, autoimmune disease, and tissue repair. In a piglet infection model of Glaesserella parasuis, integrated bulk RNA-seq and single-cell RNA-seq of porcine alveolar macrophages identified a pathogenic macrophage program associated with severe disease that included CCL2 among a 16-gene signature linked to progression. In parallel, a systematic review and meta-analysis of periodontitis found that circulating CCL2 levels were significantly elevated in affected individuals, including analyses restricted to systemically healthy participants, supporting its association with systemic inflammatory burden.

Several publications explored CCL2-directed therapeutic strategies. In breast cancer, CRISPR-Cas9-mediated suppression of the MCP-1/CCL2 gene using an MCM-41-based lysine/cysteine-modified nanocarrier reduced proliferation, migration, and invasion of MDA-MB-231 cells, highlighting a non-viral gene-editing approach. Another breast cancer study developed chimeric CCL2- and CCL8-diphtheria toxin cytotoxic peptides and evaluated their antitumor activity against human breast tumors. In lung adenocarcinoma, GINS1 was reported to promote an immunosuppressive microenvironment by driving M2 macrophage polarization via the CCL2 axis, linking CCL2 signaling to tumor immune evasion and poor response to immune checkpoint blockade.

CCL2 has also been investigated in inflammatory and regenerative settings. In lupus nephritis, MCP-1/CCL2 was described as a critical mediator of monocyte recruitment and renal inflammation, and folic acid-functionalized fullerene nanostructures were designed as potential MCP-1 inhibitors with improved docking affinity and low predicted toxicity. In diabetic wound healing, a distinct CCL2-expressing adipose-derived stem cell subpopulation was identified; exosomes from these cells were enriched in CCL2 and other factors, accelerated wound closure in mice, promoted angiogenesis, collagen deposition, and M2-macrophage polarization, and acted through the CCL2-ACKR1 axis to activate PI3K/AKT/mTOR/HIF-1α signaling in endothelial cells.

Additional work linked CCL2 targeting to inflammatory injury and cytokine modulation. Anti-CCL2-conjugated platelets were reported to attenuate early allograft and ischemia-reperfusion injury by inhibiting monocyte infiltration. In women with breast cancer undergoing chemotherapy, strength training altered selected serum cytokines, including increases in interleukin-6 and IL-17 in the exercise group, although CCL2 itself was not among the cytokines reported as changed. Together, these publications reinforce CCL2 as a central mediator of monocyte recruitment, macrophage polarization, and inflammatory tissue remodeling, while also supporting its use as a target for gene editing, nanomedicine, peptide cytotoxins, and cell-based extracellular vesicle therapies.

Background PMIDs

• [PMID 41443126]
• [PMID 41920265]

Result PMIDs

• [PMID 41529529]
• [PMID 41663028]
• [PMID 41785046]
• [PMID 41891237]
• [PMID 41988912]
• [PMID 41999676]
• [PMID 42002091]
• [PMID 42044858]
• [PMID 42084042]
• [PMID 42089374]
• [PMID 42105691]
• [PMID 42143779]
• [PMID 42275210]
• [PMID 42300455]
• [PMID 42300751]
• [PMID 42332153]
• [PMID 42341081]
• [PMID 42388654]

Target PMIDs

• [PMID 41443126]
• [PMID 41910651]
• [PMID 42033160]
• [PMID 42118345]
• [PMID 42295485]
• [PMID 42350900]
• [PMID 42385858]
• [PMID 42390481]
• [PMID 42410501]